Brentuximab vedotin
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-BRENTUXIMAB-VEDOTIN |
|---|---|
| Type | Drug |
| Aliases | AdcetrisБрентуксимаб ведотин |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AITL DIS-ALCL DIS-CHL DIS-MF-SEZARY |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Anti-CD30 antibody-drug conjugate (MMAE payload) |
|---|---|
| Mechanism | CD30-targeted IgG1 conjugated to MMAE via cleavable linker — internalized by CD30+ cells, releases MMAE intracellularly → microtubule disruption → apoptosis. |
| Typical dosing | ALCL/PTCL CD30+ 1L (CHP-Bv): 1.8 mg/kg IV day 1 of 21-day cycle × 6. Hodgkin 1L (A+AVD): 1.2 mg/kg IV days 1+15 of 28-day cycle × 6. Mycosis fungoides r/r (CD30+ ≥10%): 1.8 mg/kg IV every 3 weeks. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Progressive multifocal leukoencephalopathy (PML, rare)
Notes
Used in: 1L T-cell lymphomas with CD30+ (ALCL universal CD30+; ~40-60% PTCL NOS / AITL CD30+) — ECHELON-2 trial showed CHP-Bv superior to CHOP. 1L Hodgkin (A+AVD = ABVD with brentuximab replacing bleomycin — ECHELON-1; bleomycin removed due to lung toxicity additive risk). R/R cutaneous lymphomas (MF/Sézary CD30+, primary cutaneous ALCL). NEVER combine with bleomycin. Ukraine: registered, NOT НСЗУ-reimbursed.
Used By
Contraindications
CI-HBV-NO-PROPHYLAXIS- CI-HBV-NO-PROPHYLAXIS
Regimens
REG-A-AVD- A+AVD (Brentuximab vedotin + Adriamycin + Vinblastine + Dacarbazine), 6 cyclesREG-BRENTUXIMAB-MAINTENANCE-ALCL- Brentuximab vedotin maintenance post-ASCT for high-risk systemic ALCL (AETHERA-style, 16...REG-BRENTUXIMAB-MAINTENANCE-CHL- Brentuximab vedotin maintenance post-ASCT for high-risk cHL (AETHERA, 16 cycles)REG-BV-MONO-MF- Brentuximab vedotin monotherapy for CD30+ MF/cutaneous ALCL (1.8 mg/kg IV q3 weeks)REG-BV-MONO-SYSTEMIC-ALCL- Brentuximab vedotin monotherapy (1.8 mg/kg IV q3 weeks × up to 16 cycles) for r/r systemi...REG-CHP-BV- Brentuximab vedotin + CHP (CHP-Bv), 6 cycles (CD30+ T-cell lymphomas)